There have been many recent therapeutic advances in human immunodeficiency virus (HIV), aiming to improve rates of viral suppression, reduce treatment burden, and improve treatment adherence. Current HIV guidelines provide recommendations for managing patients with HIV, including treatment initiation, therapy switching, and individualized treatment regimens for special populations. Rapid antiretroviral therapy (ART) initiation is imperative for early virologic suppression after HIV infection, as it improves health outcomes and decreases transmission. All individuals living with HIV should be offered ART following a confirmed diagnosis, with same-day initiation available. However, despite the benefits of early treatment, ART initiation is often delayed.
This CME Outfitters BriefCase focuses on incorporating the latest evidence-based and guideline-directed treatment strategies for a patient who has been newly diagnosed with HIV.
At the end of this CME/CE activity, participants should be able to incorporate the latest evidence-based and guideline-directed treatment strategies in the management of patients newly diagnosed with HIV.
The following learning objectives pertain only to those requesting CNE or CPE credit: Assess the latest evidence-based and guideline-directed treatment strategies in the management of patients newly diagnosed with HIV.
Supported by independent educational grants from Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare. The supporters were not involved in the development of content or the selection of faculty for this educational activity.
Infectious disease specialists, primary care physicians, PAs, nurse practitioners, nurses, pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gandhi has no disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-162-H01-P.
Call us at 877.CME.PROS (877.263.7767).